29 September 2026
- Financial press releases
- €6.5 million collected from paid early access programs; after recognition of rebates and a €4.3 million non-cash change in accounting estimate, reported IFRS revenue amounted to €(1.2) million.
- Net cash used in operating activities was reduced by 37% to €1.6 million.
- GS010/LUMEVOQ® manufacturing technology transfer to Catalent successfully completed; manufacturing of a new GMP batch for early access programs has started.
- REVISE dose-ranging study is on track, with the last patient scheduled for December 2026.